Compare
Perspective Therapeutics, Inc. vs Phathom Pharmaceuticals, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Altimmune, Inc.
| Latest fiscal year | Perspective Therapeutics, Inc. CATX | Phathom Pharmaceuticals, Inc. PHAT | Tonix Pharmaceuticals Holding Corp. TNXP | Altimmune, Inc. ALT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $175.11M | $13.11M | $41.0K |
| Revenue growth (YoY) | n/a | +216.9% | +29.8% | +105.0% |
| Gross margin | n/a | 87.1% | 49.3% (computed) | n/a |
| Operating margin | n/a | -91.4% | -959.1% | n/m |
| Net margin | n/a | -126.3% | -946.2% | n/m |
| Net income | -$103.12M | -$221.25M | -$124.02M | -$88.09M |
| EPS (Diluted) | -$1.40 | -$3.03 | -$14.57 | -$1.00 |
| Operating cash flow | -$82.48M | -$166.78M | -$99.84M | -$67.53M |
| Free cash flow | -$95.23M | -$167.00M | -$103.21M | -$67.55M |
| Cash & equivalents | $30.63M | $129.97M | $207.64M | $43.76M |
| Total assets | $266.97M | $259.15M | $277.17M | $279.93M |
| Total liabilities | $59.94M | $697.32M | $32.02M | $55.04M |
| Shareholders' equity | $207.03M | -$438.17M | $245.15M | $224.89M |
| Return on year-end equity | -49.8% | n/a | -50.6% | -39.2% |
| Shares outstanding | 74.34M | 71.42M | 12.79M | 110.88M |
Revenue, most recent five fiscal years
| Fiscal year | Perspective Therapeutics, Inc. | Phathom Pharmaceuticals, Inc. | Tonix Pharmaceuticals Holding Corp. | Altimmune, Inc. |
|---|---|---|---|---|
| Latest | $1.43M Ended 2023-12-31 | $175.11M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $41.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2022-12-31 | $55.25M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | $20.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $682.0K Ended 2023-12-31 | $7.77M Ended 2023-12-31 | $426.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2022-12-31 | n/a | -$68.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $4.41M Ended 2021-12-31 |